



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : G01N 33/53, C07K 14/00	A1	(11) International Publication Number: WO 97/08550 (43) International Publication Date: 6 March 1997 (06.03.97)
(21) International Application Number: PCT/US96/12153 (22) International Filing Date: 24 July 1996 (24.07.96) (30) Priority Data: 08/520,637 29 August 1995 (29.08.95) US (71) Applicant: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES [US/US]; 10010 North Torrey Pines Road, La Jolla, CA 92037 (US). (72) Inventors: EVANS, Ronald, M.; 1471 Cottontail Lane, La Jolla, CA 92037 (US). SCHULMAN, Ira, G.; 8538 Villa La Jolla Drive #173, La Jolla, CA 92037 (US). (74) Agent: REITER, Stephen, E.; Pretty, Schroeder, Brueggemann & Clark, Suite 2000, 444 South Flower Street, Los Angeles, CA 90071 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: RETINOID X RECEPTORS AND COMPONENTS OF THE BASAL TRANSCRIPTION MACHINERY		
(57) Abstract The retinoid X receptor (RXR) participates in a wide array of hormonal signaling pathways either as a homodimer or as a heterodimer with other members of the steroid/thyroid hormone superfamily of receptors. In accordance with the present invention, the ligand-dependent transactivation function of RXR has been characterized and the ability of RXR to interact with components of the basal transcription machinery has been examined. <i>In vivo</i> and <i>in vitro</i> experiments indicate the RXR ligand binding domain makes a direct, specific and ligand-dependent contact with a highly conserved region of the TATA binding protein (TBP). The ability of mutations that reduce ligand-dependent transcription by RXR to disrupt the RXR-TBP interaction <i>in vivo</i> and <i>in vitro</i> suggests that RXR makes direct contact with the basal transcription machinery in order to achieve activation.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Retinoid X receptors and components of the basal transcription machinery

ACKNOWLEDGEMENT

This invention was made with Government support under Grant No. GM 26444, awarded by the National Institutes of Health. The Government has certain rights in
5 the invention.

FIELD OF THE INVENTION

The present invention relates to methods for the modulation of nuclear receptor mediated processes. In a particular aspect, the present invention relates to methods
10 for the identification of compounds useful for such modulation, as well as compositions useful for such assays.

BACKGROUND OF THE INVENTION

Members of the steroid/thyroid hormone superfamily of receptors regulate expression of complex
15 gene networks involved in vertebrate development, differentiation and homeostasis. A defining characteristic of these receptors lies in part in their ability to function as ligand-activated transcription factors. Retinoid X receptors (RXRs) occupy a central position in
20 the function and activity of many members of this superfamily of receptors. For example, by forming heterodimers with retinoic acid receptors (RARs), thyroid hormone receptors (TRs), vitamin D receptors (VDRs), peroxisome proliferator activated receptors (PPARs) and
25 several orphan receptors, RXRs participate in a diverse array of signaling pathways (Mangelsdorf et al., *Recent Prog. in Hormone Res.* 48:99-121 (1993)). The ability of

RXR homodimers to respond to 9-*cis* retinoic acid identifies still another signaling pathway influenced by this nuclear receptor. The critical role of RXRs in the function of nuclear receptors is further highlighted by the structural
5 and functional conservation between vertebrate RXRs and the *Drosophila* nuclear receptor *ultraspiracle* (Oro et al., *Nature* 347:298-301 (1990); and Yao et al., *Cell* 71:63-72 (1992)).

The mechanism by which RXR (and other nuclear
10 receptors) activates transcription is poorly understood. Numerous studies have defined two independent transactivation functions (tau domains; τ) in most members of the steroid/thyroid hormone superfamily of receptors. These activation functions include a constitutive
15 activation function (τ_1 or AF-1) present in the amino-terminal region and a ligand-dependent activation function (τ_c or AF-2) present in the carboxy-terminal 200-250 amino acids. The carboxy-terminal domain of nuclear receptors is complex, mediating ligand-dependent activation, receptor
20 homo- and heterodimerization and ligand binding (Parker, M.G., *Curr. Opin. in Cell Biol.* 5:499-504 (1993); and Stunnenberg, H.G., *BioEssays* 15:309-315 (1993)). Binding of ligand is thought to induce a conformational change in receptors that leads to activation of transcription (Allan
25 et al., *J. Biol. Chem.* 267:19513-19520 (1992); Beekman et al., *Mol. Endocrinol.* 7:1266-1274 (1993); Toney et al., *Biochemistry* 32:2-6 (1993); Leid, M., *J. Biol. Chem.* 269:14175-14181 (1994)).

It is not currently known how activated receptors
30 propagate their signals to the basal transcription machinery. Direct interactions between the basal transcription factor TFIIB and several nuclear receptors have been reported (Ing et al., *J. Biol. Chem.* 267:17617-17623 (1992); Baniahmad et al., *Proc. Natl. Acad. Sci. USA*
35 90:8832-8836 (1993); Fondell et al., *Genes & Devel.* 7:1400-

1410 (1993); Blanco et al., *Proc. Natl. Acad. Sci. USA* 92:1535-1539 (1995); and MacDonald et al., *J. Biol. Chem.* 270:4748-4752 (1995)). The nuclear receptor-TFIIB interaction does not appear to be influenced by ligand. 5 Indeed, it has been suggested that interaction between TR and TFIIB may be associated with transcriptional repression (Baniahmad et al., (1993) supra; and Fondell et al., supra). The identification of several novel proteins suggested to be involved in ligand-activated transcription 10 by nuclear receptors (Halachmi et al., *Science* 264:1455-1458 (1994); Jacq et al., *Cell* 79:107-118 (1994); Berkanstam et al., *Cell* 69:401-412 (1992); Cavailles et al., *Proc. Natl. Acad. Sci. USA* 91:10009-10013 (1994); and Lee et al., *Nature* 374:91-94 (1995)) suggests that 15 coactivators or bridging factors may also be involved in transmitting the signal from ligand activated receptors to the basal transcription apparatus.

In view of the limited understanding of how activated receptors propagate their signals to the basal 20 transcription machinery, what is needed in the art is a better understanding of such signalling processes. The identification of components of the basal transcription machinery involved in such signalling would be of great value. The identification of such components would also 25 facilitate the development of assays for novel ligands for nuclear receptors.

BRIEF DESCRIPTION OF THE INVENTION

In accordance with the present invention, we have identified components of the basal transcription machinery 30 involved in RXR signalling. Further in accordance with the present invention, the ligand-dependent transactivation function of RXR has been characterized and the ability of RXR to interact with components of the basal transcription machinery has been examined. *In vivo* and *in vitro*

experiments indicate the RXR ligand binding domain makes a direct, specific and ligand-dependent contact with a highly conserved region of the TATA binding protein (TBP). The ability of mutations that reduce ligand-dependent transcription by RXR to disrupt the RXR-TBP interaction *in vivo* and *in vitro* suggests that RXR makes direct contact with the basal transcription machinery in order to achieve activation.

Recently a small region at the carboxy terminus of RXR has been identified that is required for ligand-activated transcription (Durand et al., *EMBO J.* 13:5370-5382 (1994); Leng et al., *Mol. Cell. Biol.* 15:255-263 (1995); and Zhang et al., *Mol. Cell. Biol.* 14:4311-4323 (1994)). This activation domain (γ C), which is conserved among most members of the steroid and thyroid hormone receptor superfamily (Danielian et al., *EMBO J.* 11:1025-1033 (1992)), functions as a constitutive activator when fused to a heterologous DNA binding domain. In accordance with the present invention, the transactivation properties of RXR have been examined in both mammalian and in *Saccharomyces cerevisiae* cells. The ability of the RXR γ C domain to function in both mammalian cells and in *S. cerevisiae* suggests that activation pathways mediated by RXR are conserved. Both *in vivo* and *in vitro* experiments indicate the RXR γ C domain mediates an interaction between the RXR ligand binding domain and the conserved carboxy-terminal domain of the TATA binding protein (TBP). Mutations in either the RXR γ C domain or in TBP disrupt this interaction, suggesting that the RXR-TBP interaction plays a functional role in transactivation by RXR.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 illustrates the effect of point mutations in the RXR γ c domain on the ability of RXR to induce transactivation.

5 Figure 1A presents transactivation results with fusions between the GAL4 DNA binding domain and the last 19 amino acids of human RXR α (amino acids 444-462) and the last 20 amino acids of human TR α (amino acids 391-410). Bold letters identify the mutations introduced into the
10 RXR444-462 sequence. Dotted lines indicate all other amino acids are identical to the RXR444-462 sequence. The activity of GAL4RXR444-462 was set at 100%.

 Figure 1B presents transactivation results with constructs prepared by introducing the point mutations
15 described in Figure 1A into the GAL4-RXR ligand binding domain fusion (GAL4RXR197-462). GAL4RXR197-443 represents the γ c truncation. After transfection, CV1 cells were cultured in the presence (filled bars) or absence (open bars) of 100 nM LG69 (an RXR specific ligand) for 36 hours.
20 Fold induction relative to the reporter alone is reported.

Figure 2 presents results of the yeast two-hybrid assay to assess the interaction between receptor ligand binding domains and various components of the basal transcription machinery.

25 Figure 2A presents results obtained employing fusions between the GAL4 activation domain and RXR, RAR, and TR; activation domain fusions were cotransformed into the strain Y190 along with fusions between the GAL4 DNA binding domain and the conserved carboxy terminal domain of
30 human TBP. The results presented herein illustrate the interaction between receptor ligand binding domains and TBP. The activity of the GAL4 activation domain alone was

measured only in the absence of ligand. Beta-galactosidase activity was measured after growth for 16 hours in the presence (filled bars) or absence (open bars) of 1 μ M 9-*cis* retinoic acid (RXR and RAR) or 1 μ M TRIAC (TR). No
5 interaction between receptor and TBP is detected in the absence of ligand.

Figure 2B illustrates the interaction between RXR ligand binding domain mutants and TBP. Only activity in the presence of 9-*cis* retinoic acid is shown. No
10 interaction between the mutants and TBP is detected in the absence of 9-*cis* retinoic acid. Point mutants consist of amino acids 197-462 of RXR. RXR197-443 represents the *tc* truncation.

Figure 2C repeats the experiments summarized in
15 Figure 2A, using full length *Drosophila* TAF110 in place of human TBP.

Figure 2D illustrates the interaction between RXR ligand binding domain mutants and TAF110. Only activity in the presence of 9-*cis* retinoic acid is shown. No
20 interaction between the mutants and TAF110 is detected in the absence of 9-*cis* retinoic acid.

Figure 3 demonstrates that point mutations in the basic repeat of TBP disrupt the interaction with RXR *in vivo*.

Figure 3A presents results when a fusion between
25 the GAL4 activation domain and RXR (amino acids 197-462) was cotransformed into a host (strain Y190) along with fusions between the GAL4 DNA binding domain and human TBP (the conserved carboxy terminal domain, amino acids 151-
30 335). Y233G, R321E/K232E/R235E, V236G and V237G identify the amino acid changes introduced into TBP. Beta-galactosidase activity was measured after growth for 16

hours in the presence of 1 μ M 9-*cis* retinoic acid as described in the Example section.

Figure 3B presents results when fusions between the GAL4 activation domain and RXR γ c mutants were
5 cotransformed into a host (strain Y190) along with a fusion between the GAL4 DNA binding domain and the TBP mutant V237G described in reference to Figure 3A. Beta-galactosidase activity was measured after growth for 16
10 hours in the presence (filled bars) or absence (open bars) of 1 μ M 9-*cis* retinoic acid as described in the Example section. Point mutants consist of amino acids 197-462 of RXR. RXR197-443 represents the γ c truncation. Note the difference in scale between A and B.

DETAILED DESCRIPTION OF THE INVENTION

15 In accordance with the present invention, mutations of the ligand-dependent activation function (γ c) of RXR are exploited to examine the role of this domain in ligand-dependent transactivation. The γ c domain encodes a potential amphipathic alpha helix with hydrophobic and
20 negatively charged faces. This domain is necessary for ligand-dependent activation of transcription by RXR and is sufficient to activate transcription when fused to a heterologous DNA binding domain in both mammalian cells and *S. cerevisiae* (see Figure 1). Using both the yeast two-
25 hybrid assay and *in vitro* GST pull-down experiments, the RXR ligand binding domain has been shown to make a direct and specific contact with the basic repeat present in the conserved carboxy-terminal domain of the TATA binding
30 protein (TBP; see Figures 2 and 3). The ability of mutations in the γ c domain that reduce the transactivation ability of RXR to disrupt the RXR-TBP interaction *in vivo* and *in vitro* suggests this interaction has functional significance.

Both RXR and TR interact with a second component of the TFIID complex, TAF110 (see Figure 2B). The finding that a functional *rc* domain is not required for the RXR-TAF110 interaction (see Figure 2C) indicates the TAF110
5 interaction is not sufficient for activation of transcription. Nevertheless, the ability of RXR to interact with two members of the TFIID complex that do not interact with each other (Hoey et al., *Cell* 72:247-260 (1993)) may be important for receptor function.

10 Accordingly, in accordance with the present invention, there are provided methods to identify compounds which are agonists or antagonists for retinoid X receptor (RXR). Invention method comprises:

contacting:

15 a first fusion protein comprising the GAL4 DNA binding domain, operatively associated with a transactivation dependent, ligand dependent component of the basal transcription machinery (or, alternatively, operatively associated with
20 the RXR ligand binding domain),

a second fusion protein comprising the GAL4 activation domain, operatively associated with the RXR ligand binding domain (or, alternatively, operatively associated with a transactivation
25 dependent, ligand dependent component of the basal transcription machinery),

said putative agonist or antagonist for RXR,
and

30 a reporter construct comprising a GAL4 response element operatively linked to a reporter gene;

contacting:

a third fusion protein comprising the GAL4 DNA binding domain (or, alternatively, the GAL4

activation domain), operatively associated with a transactivation independent, ligand dependent component of the basal transcription machinery, said second fusion protein (or, 5 alternatively, said first fusion protein), said putative agonist or antagonist for RXR, and said reporter construct; and thereafter

identifying as agonists those compounds which 10 induce transactivation in the presence of both said transactivation dependent, ligand dependent component and said transactivation independent, ligand dependent component of the basal transcription machinery, identifying as antagonists those compounds which 15 induce transactivation in the presence of said transactivation independent, ligand dependent component of the basal transcription machinery, but not in the presence of said transactivation dependent, ligand dependent component of the basal transcription machinery, and 20 identifying those compounds which fail to induce transactivation in the presence of either said transactivation dependent, ligand dependent component or said transactivation independent, ligand dependent component of the basal transcription machinery as neither 25 agonists nor antagonists of hormone-mediated pathways involving RXR.

Optionally, compounds which fail to induce transactivation in the presence of either said transactivation dependent, ligand dependent component or 30 said transactivation independent, ligand dependent component of the basal transcription machinery can be further tested for the ability to bind RXR. Those compounds which do not bind are neither agonists nor antagonists of RXR, while those compounds which bind RXR 35 (but fail to induce transactivation thereof in the presence

of either of the above-described components of the basal transcription machinery) are presumably involved in other (i.e., non-hormone mediated) signalling pathways.

Various constructs employed in the practice of the present invention are well known in the art. Thus, the GAL4 DNA binding domain, the GAL4 activation domain, GAL4 response elements and various members of the basal transcription machinery have all been well characterized and extensively discussed in the art. For example, the DNA binding domain of the yeast GAL4 protein comprises at least the first 74 amino acids thereof (see, for example, Keegan et al., *Science* 231:699-704 (1986)). Preferably, the first 90 or more amino acids of the GAL4 protein will be used, with the first 147 amino acid residues of yeast GAL4 being presently most preferred.

The GAL4 fragment comprising the DNA binding domain employed in the practice of the present invention can be incorporated into any of a number of sites within the receptor protein. For example, the GAL4 DNA binding domain can be introduced at the amino terminus of the receptor protein, or the GAL4 DNA binding domain can be substituted for the native DNA binding domain of the receptor, or the GAL4 DNA binding domain can be introduced at the carboxy terminus of the receptor protein, or at other positions as can readily be determined by those of skill in the art.

Exemplary GAL4 response elements are those containing the palindromic 17-mer:

5'-CGGAGGACTGTCCTCCG-3' (SEQ ID NO:1),

such as, for example, 17MX, as described by Webster et al., in *Cell* 52:169-178 (1988), as well as derivatives thereof. Additional examples of suitable response elements include

those described by Hollenberg and Evans in *Cell* 55:899-906 (1988); or Webster et al. in *Cell* 54:199-207 (1988).

Numerous components of the basal transcription machinery have been described, e.g., TBP, TAF, TAF110, 5 TFIIA, TFIIB, TFIID, TFIIE, TFIIIF, TFIIH, SUG1, TRIP1, TIF1, and the like.

Exemplary transactivation dependent/ligand dependent components of the basal transcription machinery include the TATA binding protein (TBP), SUG1, TRIP1, and 10 the like.

An exemplary transactivation independent, ligand dependent component of the basal transcription machinery is the TBP mutant, TAF110.

Reporter constructs contemplated for use in the 15 practice of the present invention comprise:

- (a) a promoter that is operable in the host cell,
 - (b) a hormone response element, and
 - (c) a DNA segment encoding a reporter protein, 20
- wherein the reporter protein-encoding DNA segment is operatively linked to the promoter for transcription of the DNA segment, and
- 25 wherein the hormone response element is operatively linked to the promoter for activation thereof.

Hormone response elements contemplated for use in the practice of the present invention are composed of at 30 least one direct repeat of two or more half sites separated by a spacer of one nucleotide. The spacer nucleotide can be selected from any one of A, C, G or T. Each half site

of response elements contemplated for use in the practice of the invention comprises the sequence

-RGBNNM-,

wherein

- 5 R is selected from A or G;
 B is selected from G, C, or T;
 each N is independently selected from
 A, T, C, or G; and
 M is selected from A or C;

- 10 with the proviso that at least 4 nucleotides of
said -RGBNNM- sequence are identical with the nucleotides
at corresponding positions of the sequence -AGGTCA-.
Response elements employed in the practice of the present
invention can optionally be preceded by N_x, wherein x falls
15 in the range of 0 up to 5.

Presently preferred response elements contain at least one copy (with one, two or three copies most common) of the minimal sequence:

AGGACA A AGGTCA (SEQ ID NO:2).

- 20 As noted above, the minimal sequence can optionally be flanked by additional residues, for example, as in the sequence:

GGACC AGGACA A AGGTCA CGTTC (SEQ ID NO:3).

- Exemplary reporter genes include chloramphenicol
25 transferase (CAT), luciferase (LUC), beta-galactosidase (β -gal), and the like. Exemplary promoters include the simian virus (SV) promoter or modified form thereof (e.g., Δ SV), the thymidine kinase (TK) promoter, the mammary tumor virus (MTV) promoter or modified form thereof (e.g., Δ MTV),
30 and the like [see, for example, Mangelsdorf et al., in *Nature* 345:224-229 (1990), Mangelsdorf et al., in *Cell* 66:555-561 (1991), and Berger et al., in *J. Steroid Biochem. Molec. Biol.* 41:733-738 (1992)].

As used herein in the phrase "operative response element functionally linked to an operative reporter gene", the word "operative" means that the respective DNA sequences (represented, for example, by the terms "GAL4 response element" and "reporter gene") are operational, i.e., work for their intended purposes; the word "functionally" means that after the two segments are linked, upon appropriate activation by a ligand-receptor complex, the reporter gene will be expressed as the result of the fact that the "GAL4 response element" was "turned on" or otherwise activated.

Any cell line can be used as a suitable "host" for the functional bioassay contemplated for use in the practice of the present invention. Thus, cells contemplated for use in the practice of the present invention include transformed cells, non-transformed cells, neoplastic cells, primary cultures of different cell types, and the like. Exemplary cells which can be employed in the practice of the present invention include Schneider cells, CV-1 cells, HuTu80 cells, F9 cells, NTERA2 cells, NB4 cells, HL-60 cells, 293 cells, Hela cells, yeast cells, and the like. Preferred host cells for use in the functional bioassay system are COS cells and CV-1 cells. COS-1 (referred to as COS) cells are monkey kidney cells that express SV40 T antigen (Tag); while CV-1 cells do not express SV40 Tag. The presence of Tag in the COS-1 derivative lines allows the introduced expression plasmid to replicate and provides a relative increase in the amount of receptor produced during the assay period. CV-1 cells are presently preferred because they are particularly convenient for gene transfer studies and provide a sensitive and well-described host cell system.

The above-described cells (or fractions thereof) are maintained under physiological conditions when contacted with physiologically active compound.

"Physiological conditions" are readily understood by those of skill in the art to comprise an isotonic, aqueous nutrient medium at a temperature of about 37°C.

In the invention assay, the RXR-TBP interaction is ligand-dependent. Invention assays and transactivation experiments are carried out with ligand concentrations well above the K_d values for LG69 and 9-*cis* retinoic acid (Allegretto et al., *J. Biol. Chem.* 268:26625-26633 (1993)) such that small changes in ligand affinity would not be expected to have significant effects. The ability of RXR γ c domain mutants to interact in a ligand-dependent fashion with TAF110 (see Figure 2D) and to bind ligand *in vitro* indicates that the absence of an interaction between the mutants and TBP does not result from a defect in ligand binding.

Taken together, these results suggest the RXR γ c domain directly interacts with TBP and that this interaction is regulated by ligand. This conclusion is supported by the *in vitro* interaction between the GAL4- γ c domain fusion and TBP. Finally, the ability to recover the interaction between the RXR γ c domain mutant and TBP by introducing a second site mutation in TBP (see Figure 3B) further supports the conclusion that the γ c domain directly interacts with TBP. The ability of multiple factors to contact the basic repeat of TBP suggests that interaction with this domain of TBP may represent a common mechanism for transactivation.

The observation that RAR and TR do not interact with TBP (see Figure 2A) suggests that different RXR/nuclear receptor heterodimers may activate transcription by contacting different components of the transcriptional machinery. This conclusion is consistent with the observation that ligand responsiveness of RXR can be modified by heterodimeric pairing. The ability of

mutations in the RXR γ c domain to adversely effect
transactivation by heterodimers suggests that when
complexed as a heterodimer, the RXR γ c domain can be
redirected to a different coactivator or component of the
5 basal transcription machinery.

In accordance with another embodiment of the
present invention, there are provided RXR mutants which
retain the ability to bind 9-*cis*-retinoic acid, but which
are not activated by 9-*cis*-retinoic acid. Examples of such
10 mutants include RXR mutant D444A, RXR mutant T445A, RXR
mutant P446A, RXR mutant I447A, RXR mutant D448A, RXR
mutant T449A, RXR mutant F450P, RXR mutant L451A, RXR
double mutant M454A, L455A, RXR double mutant E453K, E456K,
RXR mutant M452A, and the like.

15 In accordance with yet another embodiment of the
present invention, there are provided methods to identify
agonists of retinoid X receptors. Invention method
comprises:

20 contacting cells containing an RXR mutant as
described above (i.e., having the ability to bind
9-*cis*-retinoic acid, but lacking the ability to
be activated by 9-*cis*-retinoic acid) with a
putative RXR ligand, wherein said cells contain
an RXR response element operatively linked to a
25 reporter gene, and thereafter

monitoring the expression of reporter gene
product.

In an alternate aspect of this embodiment, there
are also provided methods to identify antagonists of
30 retinoid X receptors. This method comprises:

5 contacting cells containing an RXR mutant
 (as described above) with a constant amount of an
 RXR agonist and variable amounts of a putative
 antagonist therefor, wherein said cells contain
 an RXR response element operatively linked to a
 reporter gene, and thereafter

 monitoring the expression of reporter gene
 product as a function of the amount of putative
 antagonist administered to said test cell.

10 In accordance with yet another embodiment of the
 present invention, there are provided methods to detect
 ligand-dependent interactions between retinoid X receptor
 and one or more components of the basal transcription
 machinery. Invention methods comprise:

15 contacting:

 a first fusion protein comprising the GAL4
 DNA binding domain, operatively associated with
 a first component of the basal transcription
 machinery (or, alternatively, operatively
20 associated with the RXR ligand binding domain),
 a second fusion protein comprising the GAL4
 activation domain, operatively associated with
 the RXR ligand binding domain (or, alternatively,
 operatively associated with a first component of
25 the basal transcription machinery),
 an RXR ligand, and
 a reporter construct comprising a GAL4
 response element operatively linked to a reporter
 gene; and thereafter

30 monitoring for expression of said reporter.

 In accordance with a further aspect of this
 embodiment of the present invention, the above-described

contacting and monitoring steps can be repeated, employing a different first fusion protein (or different second fusion protein) which differs from the original first (second) fusion protein by containing a different component of the basal transcription machinery than the original first (second) fusion protein. This added step allows one to identify both transcription dependent/ligand dependent and transcription independent/ligand dependent components of the basal transcription machinery, which are useful for conducting the above-described assays.

The invention will now be described in greater detail by reference to the following non-limiting examples.

Example 1

Preparation of plasmids

For integration in *S. cerevisiae*, plasmid pRS305CYH was constructed by cloning a *Bgl*III-*Sal*I fragment from pAS1-CYH2 (gift of S. Elledge, Baylor College of Medicine) containing the ADH promoter, GAL4 DNA binding domain (amino acids 1-147), influenza hemagglutinin epitope and poly linker in the order written into BamHI-*Sal*I digested pRS305 (Sikorski and Hieter, *Genetics* 122:19-27 (1989)).

For expression of GAL4-DNA binding domain fusions of human TBP mutants in *S. cerevisiae* (see below), plasmid pG6H was constructed by PCR amplification of the GAL4 DNA binding domain-influenza hemagglutinin epitope-polylinker from pAS1-CYH2. A sequence encoding six histidines was included directly after the initiator methionine of GAL4 in the 5' oligonucleotide. The amplified product was ligated into BamHI digested pG-1 (Schena et al., In: *Vectors for constitutive and inducible gene expression in yeast*, Guthrie and Fink (eds.), (Academic Press, Inc., San Diego) pp. 389-398 (1991)).

For expression of GAL4-DNA binding domain fusions in CV1 cells, the plasmid pCMXG4epi was constructed by PCR amplification of the GAL4 DNA binding domain-influenza hemagglutinin epitope-poly linker from pAS1-CHY2 and
5 cloning into HindIII-BamHI digested pCMX (Umesono et al., *Cell* 65:1255-1266 (1991)). An optimal mammalian translation initiation sequence was included in the 5' oligonucleotide and introduced into the amino terminus of GAL4.

10 Receptor ligand binding domain fusions were cloned by PCR amplification of human RXR α (amino acids 197-462), human RAR α (amino acids 186-462) and human TR α (amino acids 121-410). A ligand binding domain fusion with
15 truncation of the τ c domain (RXR197-443) was amplified as described above, however, an in-frame stop codon was introduced into the 3' oligonucleotide at the appropriate position.

For τ c domain fusions, amino acids 444-462 of human RXR α and 391-410 of human TR α were amplified by PCR.
20 Point mutations were introduced into the RXR τ c domain by PCR using oligonucleotides with the appropriate base changes. Amplified products were ligated into NcoI-BamHI digested pRS305CYH. For expression in CV1 cells, appropriate restriction fragments from the pRS305CYH clones
25 were subcloned into pCMXG4epi.

For two-hybrid assays, GAL4-activation domain fusions of RXR, RAR and TR were constructed by cloning the same amplification products described above into NcoI-BamHI digested pACTII (S. Elledge, Baylor College of Medicine;
30 see Durfee et al., in *Genes & Development* 7:555-569 (1993)).

GAL4-DNA binding domain fusions expressing the C-terminal domain of human TBP (pAS+h180c), full length

Drosophila TAF110) and full length *Drosophila* TAF40 (pAS+dTAF40) were provided by G. Gill and R. Tjian (UC Berkeley; see Hoey et al., in *Cell* 72:247-260 (1993)). Human TBP (amino acids 155-335) was amplified by PCR in two
5 fragments. Point mutations were introduced into the appropriate oligonucleotides. After PCR, the two fragments were cloned into *NcoI/BamHI* digested pG6H. A GAL4-DNA binding domain fusion of human TFIIB was made by PCR amplification of the human cDNA and cloned into the *BamHI*
10 site of pG6H.

GST-RXR197-462 was constructed by PCR amplification of the appropriate sequences from human RXR α . The amplification products were cloned into *EcoRI-BamHI* digested pGEX2TK. All PCR-derived constructs were verified
15 by sequencing. The plasmid pGEX-TBP was the kind gift of Dr. I. Verma (Salk Institute; see Kerr et al., in *Nature* 365:412-419 (1993)). Mammalian expression constructs expressing the ligand binding domains of human RXR α , human RAR α and human TR β have been described elsewhere (Forman et
20 al., *Cell* 81:541-550 (1995)).

The luciferase reporter GAL3-TK-LUC containing three binding sites for GAL4 upstream of the TK promoter luciferase fusion was the gift of Dr. P.N. Rangarajan. GAL3-TK-LUC contains three copies of double-stranded GAL4
25 reponse element, cloned upstream of the TK promoter of TK-LUC at the *HindIII* site. TK-LUC is prepared as follows: the MTV-LTR promoter sequence was removed from the MTV-LUC plasmid described by Hollenberg and Evans in *Cell* 55:899-906 (1988) by *HindIII* and *XhoI* digest, and cloned with the
30 *HindIII-XhoI* fragment of the Herpes simplex virus thymidine kinase gene promoter (-105 to +51 with respect to the transcription start site, m, isolated from plasmid pBLCAT2, described by Luckow & Schutz in *Nucleic Acids Res.* 15:5490 (1987)) to generate parental construct TK-LUC.

Example 2Yeast Strains and Methods

The strain Y190 (MATa gal4 gal80 his3 trp1-901 ade2-101 ura3-52 leu2-3,-112 cyh^r URA3::GAL1-->lacZ
5 LYS2::GAL1-->HIS3; a gift of S. Elledge, Baylor College of
Medicine; Y190 is derived from Y153, described by Durfee et
al., supra) was used for all experiments. For beta-
galactosidase assays, a minimum of three independent
10 transformants were grown overnight at 30°C in minimal media
(0.66% YNB, 2% glucose) supplemented with the appropriate
amino acids. Cells were diluted 1:20 into fresh media and
9-cis retinoic acid of 3,3',5-triiodothyroacetic acid
(TRIAC) was added if required. Beta-galactosidase activity
was measured after 16 hours of growth at 30°C as described
15 by Rose et al., *Methods in yeast genetics* (Cold Spring
Harbor Laboratory Press, Cold Spring Harbor) (1990).

Example 3Transfection

CV1 cells were plated in 48 well plates at a
20 density of 2×10^4 cells/well in DMEM supplemented with 10%
charcoal-resin split fetal bovine serum. After growth at
37°C for 12-16 hours, cells were transfected using the
DOTAP transfection reagent following the manufacturer's
instructions (Boehringer Mannheim). For each well, 12ng of
25 GAL3-TK-LUC reporter, 36ng of the appropriate expression
constructs and as an internal control, 60ng of pCMX- β gal
DNA were transfected. DNA was introduced along with 200 μ l
of DMEM supplemented with 10% charcoal-resin split fetal
bovine serum. Cells were incubated with DNA for 5 hours at
30 37°C. The media was then removed, the cells washed once
with fresh media and 200 μ l of media with or without 9-cis
retinoic acid, T₃ (3,3',5-triiodo-L-thyronine) or vitamin D₃
was added. The RXR specific ligand LG69 (4-[1-(3,5,5,8,8-
pentamethyl-5,6,7,8-tetrahydro-2-naphthyl-1-ethenyl]benzoic

acid) and the RAR specific ligand AM580 (4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthamido)benzoic acid) were also used. Cells were harvested after 36 hours of growth at 37°C. Luciferase activity of each sample was
5 normalized by the level of beta-galactosidase activity. Each transfection was carried out in duplicate and repeated at least three times. The fold induction reported is relative to the GAL3-TK-LUC reporter alone included in each experiment.

10

Example 4RXR-TBP interaction Assay

GST-fusion proteins were induced, solubilized and bound to glutathione beads following the manufacturer's procedures (LKB-Pharmacia). After binding to glutathione
15 beads, 15 µl of the suspension was incubated with 1 to 2 µl of the appropriate ³⁵S-labeled *in vitro* translated protein for 1 hour in 500 µl of NETN (20 mM Tris-HCl, pH 7.5, 100 mM KCl, 0.7 mM EDTA, 0.5% NP40, 1 mM PMSF). Following incubation, the beads were washed three times with NETN.
20 Bound proteins were eluted with 20 µl of 1X SDS-PAGE buffer and electrophoretically separated in a SDS-10% polyacrylamide gel. The interaction of *in vitro* translated GAL4 fusions with GST-TBP was carried out using the above procedure with the following modifications. The initial
25 interaction was carried out in NETN in which KCl was replaced with 0.3M NaCl and non-fat dry milk was added to final concentration of 0.5% (w/v). Following incubation, the beads were washed three times with NETN in which the NaCl concentration was increased to 0.5M and non-fat dry
30 milk was added to final concentration of 0.5% (w/v). Following fixation gels were treated with 1 M salicylic acid, dried and subjected to autoradiography.

Example 5Mutagenesis of the RXR γ C domain

The carboxy terminal 19 amino acids of RXR and 20 amino acids of TR have been shown to activate transcription when fused to heterologous DNA binding domains (Figure 1; (Durand et al., supra; Leng et al., supra; Zhang et al., supra; Baniahmad et al., *Mol. Cell. Biol.* 15:76-86 (1995); Barettino et al., *EMBO J.* 13:3039-3049 (1994); and Tone et al., *J. Biol. Chem.* 269:31157-31161 (1994)). This region has been proposed to form an amphipathic alpha helix with hydrophobic and negatively charged faces (Danielian et al., supra).

Figure 1A presents transactivation results with fusions between the GAL4 DNA binding domain and mutants of the last 19 amino acids of human RXR α (amino acids 444-462) and the last 20 amino acids of human TR α (amino acids 391-410). These constructs were transfected into CV1 cells along with the reporter GAL3-TK-LUC or integrated into the genome of the *S. cerevisiae* strain Y190 containing the integrated GAL1-lacZ reporter as described above. CV1 cell transfection results were normalized by cotransfection with a beta-galactosidase expression plasmid. Western blotting of *S. cerevisiae* extracts indicates the GAL4 fusions are expressed at similar levels.

Mutation of the carboxy-terminal 19 amino acids of RXR (Figure 1A) indicates that, like several other transactivation domains, the hydrophobic and acidic amino acids are critically important for function (Cress and Triezenberg, *Science* 251:87-90 (1991)). Within the hydrophobic face of the helix individual changes of phenylalanine at position 450 to proline (F450P), leucine at position 451 to alanine (L451A) and the double mutant methionine 454 to alanine/leucine 455 to alanine (M454A/L455A) severely reduce the ability of GAL4 fusions

to activate transcription when assayed in the context of the isolated γ c domain in both mammalian and *S. cerevisiae* cells. The double mutant glutamic acid 453 to lysine/glutamic acid 456 to lysine (E453K/E456K) on the charged face of the helix also eliminates the ability to the isolated γ c domain to activate transcription (Figure 1A). The single mutations E453K and E456K reduce transcription approximately 60-70%.

Mutation of methionine 452 to alanine (M452A), however, has little effect. Incorporation of these same mutations into the complete ligand binding domain (Figure 1B) or into full length receptors reduces the ability of these mutant RXRs to activate transcription in response to RXR specific ligands. Importantly, truncation of the 19 amino acids (GAL4RXR197-443) also produces a receptor that fails to activate transcription (Figure 1B). The reduction in ligand-dependent transcription observed with GAL4RXR197-443 does not appear to result from a defect in ligand binding (see Figure 2D). Taken together, the results confirm that the last 19 amino acids of RXR are both necessary and sufficient for transactivation and indicate that both the hydrophobic and charged faces of the helix residues are important for this function.

Example 6

RXR interacts with the TATA binding protein

The finding that mutations in the RXR γ c domain have qualitatively similar effects in mammalian and *S. cerevisiae* cells (Figure 1A) suggests that RXR directly contacts a structurally and functionally conserved component of the transcription machinery. This observation is consistent with the finding that several other transcription factors, including members of the steroid and thyroid hormone receptor superfamily, interact with components of the basal transcription machinery (Ing et

al., supra; Baniahmad et al., (1993) supra; Fondell et al.,
supra; Blanco et al., supra; and MacDonald et al., supra).
Therefore, we examined the interactions between RXR and
several basal transcription factors, including the TATA
5 binding protein (TBP), TAF110, TAF40 and TFIIB, using the
both yeast two-hybrid system (Fields and Song, *Nature*
340:245-246 (1989); and Durfee et al., *Genes & Devel.*
7:555-569 (1993)) and *in vitro* protein-protein interaction
assays. As shown in Figure 2A, the two-hybrid assay
10 detects a specific and ligand-dependent interaction between
RXR and the conserved carboxy-terminal domain of TBP.

Thus, fusions between the GAL4 activation domain
and RXR, RAR, and TR and RXR τ c mutants were cotransformed
into the strain Y190 along with fusions between the GAL4
15 DNA binding domain and the conserved carboxy terminal
domain of human TBP (see Figures 2A and 2B) or full length
Drosophila TAF110 (see Figures 2C and 2D). Beta-
galactosidase activity was measured after growth for 16
hours in the presence (filled bars) or absence (open bars)
20 of 1 μ M 9-*cis* retinoic acid (RXR and RAR) or 1 μ M TRIAC
(TR; see Figures 2A and 2C). Interaction between receptor
ligand binding domains and TBP and TAF110 are shown in
Figure 2A and 2C, respectively. The activity of the GAL4
activation domain alone was measured only in the absence of
25 ligand. Note the difference in scale between Figures 2A
and 2C.

The interaction between RXR ligand binding domain
mutants and TBP and TAF110 are shown in Figures 2B and 2D,
respectively. Only activity in the presence of 9-*cis*
30 retinoic acid is shown. No interactions between the
mutants and TBP or TAF110 is detected in the absence of
9-*cis* retinoic acid. Point mutants consist of amino acids
197-462 of RXR. RXR197-443 represents the τ c truncation.
Western blotting of *S. cerevisiae* extracts indicates the

GAL4-activation domain fusions are expressed at similar levels. Interactions between TAF40 and RXR, RAR or TR were also tested and not detected. An interaction was detected between TR and TFIIB.

5 Mutations in the RXR γ c domain that eliminate the ability of RXR to activate transcription (Figure 1) eliminate a detectable interaction between RXR and TBP (Figure 2B). Although TR and RAR have γ c domains that exhibit significant sequence homology to the RXR γ c domain,
10 an interaction between TR or RAR and TBP is not detected (Figure 2A). Nevertheless, the same region of TR activates transcription in *S. cerevisiae* when fused to the GAL4 DNA binding domain. The failure to detect an interaction between RAR and TBP or between TR and TBP suggests that
15 transactivation by RXR homodimers may utilize different components of the transcription machinery than transactivation by RAR and TR heterodimers.

Figure 2C also shows that RXR can make a ligand-dependent interaction with a second component of the TFIID
20 complex, TAF110. The interaction between RXR and TAF110 is detectable even when γ c domain mutants are analyzed, indicating the functional state of the γ c domain is not important for the interaction (Figure 2D). Nevertheless, the ability to detect ligand-dependent interactions between
25 transcriptionally defective RXR mutants and TAF110 suggests that mutations in the RXR γ c domain do not have large effects on ligand binding. The observation that TR (Figure 2C) also interacts with TAF110 suggests this basal factor may be a common target for multiple nuclear receptors.

30 Although the results of the two-hybrid assay suggest RXR makes a direct protein-protein interaction with TBP, the possibility that this interaction is mediated by a conserved coactivator cannot be ruled out by this assay. To further characterize the interaction between RXR and

TBP, the ability of TBP to interact *in vitro* with bacterial expressed glutathione-S-transferase RXR fusion proteins was examined.

Thus GST pull-down experiments were carried out
5 as follows. TBP was *in vitro* transcribed and translated as described above, and incubated with equal amounts of immobilized GST-RXR197-462 or GST-RXR-E453K/E456K) as determined by coomassie stained gels. Following extensive washing of the beads, bound proteins were eluted and
10 resolved by SDS-PAGE and the gel was processed for autoradiography. When added, 1.0 μ M 9-*cis* retinoic acid was included in all buffers. Exposure time was 2 hours. Little or no interaction between TBP and GST alone is detected under these conditions.

15 Thus, the GST pull-down experiment shows a strong interaction between *in vitro* translated TBP and GST-RXR197-462. An *in vitro* interaction between GST-RXR197-462 and TAF110 is also observed. A mutation of the RXR τ c domain (E453K/E456K) that eliminates the RXR-TBP interaction in
20 the two-hybrid assay (Figure 2B) reduces the *in vitro* interaction between RXR and TBP approximately 6 fold. Similar results are observed when a full length GST-RXR fusion is used.

A direct *in vitro* interaction between TBP and the
25 τ c domain itself (GAL4RXR444-462) that is sensitive to the functional state of the τ c domain can also be detected, as follows. Equal amounts of *in vitro* translated GAL4RXR444-462, GAL4RXR444-462-E453K/E456K or GAL4(1-147) as determined by phosphorimaging analysis were incubated
30 with immobilized GST-TBP or with immobilized GST. Following extensive washing of the beads, bound proteins were eluted and resolved by SDS-PAGE and the gel was processed for autoradiography. Exposure time was 7 hours. The sensitivity of the *in vitro* interactions to mutations

in the RXR γ c domain strongly suggests the γ c domain mediates a direct interaction between RXR and TBP.

Unlike the two hybrid assay, a RXR-TBP interaction *in vitro* can be detected in the absence of
5 ligand. Addition of ligand stimulates the interaction 3-5 fold when quantitated by phosphorimaging. The detection of ligand-independent interactions *in vitro* may result from the ability of the large amounts of protein used *in vitro* to stabilize a weak interaction that cannot be detected in
10 the two-hybrid assay.

To further define the RXR-TBP interaction, mutations were introduced into well conserved amino acids present in the basic repeat of TBP and analyzed for interaction with RXR in the two-hybrid assay. This domain
15 of TBP has been shown to be a common target of several transcription factors (Lee et al., *Cell* 67:365-376 (1991); Metz et al., *Mol. Cell. Biol.* 14:6021-6029 (1994a); and Metz et al., *EMBO J.* 13:3832-3842 (1994b)). Thus, a Fusion between the GAL4 activation domain and RXR (amino acids
20 197-462) was cotransformed into the strain Y190 along with fusions between the GAL4 DNA binding domain and human TBP (the conserved carboxy terminal domain, amino acids 151-335). Y233G, R321E/K232E/R235E, V236G and V237G identify the amino acid changes introduced into TBP. Beta-galactosidase activity was measured after growth for 16
25 hours in the presence of 1 μ M 9-*cis* retinoic acid as described in Materials and Methods. Western blotting of *S. cerevisiae* extracts indicates the GAL4-TBP fusions were expressed in similar levels.

30 Figure 3A shows that the TBP mutant V237G eliminates a detectable RXR-TBP interaction. Several other mutations in this region of TBP, including V236G, have no effect.

The finding that a single point mutation in TBP could disrupt the interaction with the wildtype RXR ligand binding domain prompted an examination of the ability of TBP-V237G to interact with the RXR γ c mutants. Thus, fusions between the GAL4 activation domain and RXR γ c mutants were cotransformed into the strain Y190 along with a fusion between the GAL4 DNA binding domain and the TBP mutants described in reference to Figure 3A. Beta-galactosidase activity was measured after growth for 16 hours in the presence (filled bars) or absence (open bars) of 1 μ M 9-cis retinoic acid as described above. Point mutants consist of amino acids 197-462 of RXR. RXR197-443 represents the γ c truncation. Note the difference in scale between A and B.

As shown in Figure 3B, a positive and ligand-dependent interaction can be detected between TBP-V237G and a single RXR γ c domain mutant, M454A/L455A. Although the interaction detected between TBP-V237G and RXR-M454A/L455A is weak relative to the wildtype interaction, an approximate 10-fold ligand-dependent induction of the interaction is observed (Figure 3B). Rescue of the RXR-TBP interaction by combining a RXR γ c domain mutant with a TBP mutant strongly suggests the RXR-TBP interaction detected in the two-hybrid assay results from a direct protein-protein interaction and is not mediated by a third factor.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

SEQUENCE LISTING

SEQ ID NO:1:

5'-CGGAGGACTGTCCTCCG-3'

SEQ ID NO:2:

5'-AGGACA A AGGTCA-3'

SEQ ID NO:3:

5'-GGACC AGGACA A AGGTCA CGTTC-3'

That which is claimed is:

1. A method to identify compounds which are agonists or antagonists for retinoid X receptor (RXR), said method comprising:

contacting:

5 a first fusion protein comprising the GAL4 DNA binding domain, operatively associated with a transactivation dependent, ligand dependent component of the basal transcription machinery,

10 a second fusion protein comprising the GAL4 activation domain, operatively associated with the RXR ligand binding domain,

said putative agonist or antagonist for RXR, and

15 a reporter construct comprising a GAL4 response element operatively linked to a reporter gene;

contacting:

20 a third fusion protein comprising the GAL4 DNA binding domain, operatively associated with a transactivation independent, ligand dependent component of the basal transcription machinery,

said second fusion protein,

said putative agonist or antagonist for RXR,

and

25 said reporter construct; and thereafter

identifying as agonists those compounds which induce transactivation in the presence of both said transactivation dependent, ligand dependent component and said transactivation independent, ligand dependent
30 component of the basal transcription machinery,

identifying as antagonists those compounds which induce transactivation in the presence of said

transactivation independent, ligand dependent component of
the basal transcription machinery, but not in the presence
35 of said transactivation dependent, ligand dependent
component of the basal transcription machinery, and
identifying those compounds which fail to induce
transactivation in the presence of either said
transactivation dependent, ligand dependent component or
40 said transactivation independent, ligand dependent
component of the basal transcription machinery as neither
agonists nor antagonists of RXR.

2. A method according to claim 1 wherein said
transactivation dependent, ligand dependent component of
the basal transcription machinery is TBP.

3. A method according to claim 2 wherein said
transactivation independent, ligand dependent component of
the basal transcription machinery is TAF110.

4. A method to identify compounds which are
agonists or antagonists for retinoid X receptor (RXR), said
method comprising:

contacting:

5 a first fusion protein comprising the GAL4
DNA binding domain, operatively associated with
the RXR ligand binding domain,
a second fusion protein comprising the GAL4
activation domain, operatively associated with a
10 transactivation dependent, ligand dependent
component of the basal transcription machinery,
said putative agonist or antagonist for RXR,
and
a reporter construct comprising a GAL4
15 response element operatively linked to a reporter
gene;

contacting:

20 said first fusion protein,
 a third fusion protein comprising the GAL4
activation domain, operatively associated with a
transactivation independent, ligand dependent
component of the basal transcription machinery,
 said putative agonist or antagonist for RXR,
and
25 said reporter construct; and thereafter

 identifying as agonists those compounds which
induce transactivation in the presence of both said
transactivation dependent, ligand dependent component and
said transactivation independent, ligand dependent
30 component of the basal transcription machinery,

 identifying as antagonists those compounds which
induce transactivation in the presence of said
transactivation independent, ligand dependent component of
the basal transcription machinery, but not in the presence
35 of said transactivation dependent, ligand dependent
component of the basal transcription machinery, and

 identifying those compounds which fail to induce
transactivation in the presence of either said
transactivation dependent, ligand dependent component or
40 said transactivation independent, ligand dependent
component of the basal transcription machinery as neither
agonists nor antagonists of RXR.

5. A method according to claim 4 wherein said
transactivation dependent, ligand dependent component of
the basal transcription machinery is TBP.

6. A method according to claim 5 wherein said
transactivation independent, ligand dependent component of
th basal transcription machinery is TAF110.

- 33 -

7. An RXR mutant which retains the ability to bind 9-*cis*-retinoic acid, but which is not activated by 9-*cis*-retinoic acid.

8. A mutant receptor according to claim 7, wherein said mutant is selected from RXR mutant D444A, RXR mutant T445A, RXR mutant P446A, RXR mutant I447A, RXR mutant D448A, RXR mutant T449A, RXR mutant F450P, RXR mutant L451A, RXR double mutant M454A, L455A, RXR double mutant E453K, E456K or RXR mutant M452A.

9. A method to identify agonists of retinoid X receptors, said method comprising:

5 contacting cells containing an RXR mutant according to claim 7 with a putative RXR ligand, wherein said cells contain an RXR response element operatively linked to a reporter gene, and thereafter

 monitoring the expression of reporter gene product.

10. A method to identify antagonists of retinoid X receptors, said method comprising:

5 contacting cells containing an RXR mutant with a constant amount of an RXR agonist and variable amounts of a putative antagonist therefor, wherein said mutant retains the ability to bind 9-*cis*-retinoic acid, but is not activated by 9-*cis*-retinoic acid, wherein said cells contain an RXR response element operatively
10 linked to a reporter gene, and thereafter

SUBSTITUTE SHEET (RULE 26)

- 34 -

monitoring the expression of reporter gene product as a function of the amount of putative antagonist administered to said test cell.

11. A fusion protein comprising the GAL4 activation domain, operatively associated with the RXR ligand binding domain.

12. A method to detect ligand-dependent interactions between retinoid X receptor and one or more components of the basal transcription machinery, said method comprising:

5 contacting:

 a first fusion protein comprising the GAL4 DNA binding domain, operatively associated with a first component of the basal transcription machinery,

10 a second fusion protein comprising the GAL4 activation domain, operatively associated with the RXR ligand binding domain,

 an RXR ligand, and

15 a reporter construct comprising a GAL4 response element operatively linked to a reporter gene; and thereafter

monitoring for expression of said reporter.

13. A method according to claim 12 further comprising repeating said contacting and monitoring steps, employing a different first fusion protein which differs from the original first fusion protein by containing a
5 different component of the basal transcription machinery than the original first fusion protein.

- 35 -

14. A method according to claim 13 wherein said component of the basal transcription machinery is selected from TBP, TAF, TAF110, TFIIA, TFIIB, TFIID, TFIIIE, TFIIF, 10 TFIIH, SUG1, TRIP1 or TIF1.

15. A method to detect ligand-dependent interactions between retinoid X receptor and one or more components of the basal transcription machinery, said method comprising:

15 contacting:

a first fusion protein comprising the GAL4 DNA binding domain, operatively associated with the RXR ligand binding domain,

20 a second fusion protein comprising the GAL4 activation domain, operatively associated with a first component of the basal transcription machinery,

an RXR ligand, and

25 a reporter construct comprising a GAL4 response element operatively linked to a reporter gene; and thereafter

monitoring for expression of said reporter.


16. A method according to claim 15 further comprising repeating said contacting and monitoring steps, employing a different second fusion protein which differs from the original second fusion protein by containing a 5 different component of the basal transcription machinery than the original second fusion protein.

17. A method according to claim 16 wherein said component of the basal transcription machinery is selected from TBP, TAF, TAF110, TFIIA, TFIIB, TFIID, TFIIIE, TFIIF, TFIIH, SUG1, TRIP1 or TIF1.

SUBSTITUTE SHEET (RULE 26)

1 / 5

FIG. 1A



2 / 5








FIG. 1B



3 / 5

**FIG. 2A****FIG. 2B**

4 / 5

**FIG. 2C****FIG. 2D**

5 / 5

**FIG. 3A****FIG. 3B**

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/12153**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :G01N 33/53; C07K 14/00.

US CL :435/7.1; 530/350.

According to International Patent Classification (IPC) r to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.1; 530/350.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim N .
X,P	SCHULMAN et al. Interactions between the retinoid X receptor and a conserved region of the TATA-binding protein mediate hormone-dependent transactivation. Proc. Natl. Acad. Sci. USA. 29 August 1995, Vol. 92, pages 8288-8292, see entire document.	1-6, 11
X ----- Y	MACDONALD et al. The vitamin D receptor interacts with general transcription factor IIB. J. Biol. Chem. 03 March 1995, Vol. 270, No. 9, pages 4748-4752, see entire document.	11 ----- 1-6

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

30 SEPTEMBER 1996

Date of mailing of the international search report

31 OCT 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL D. PARK

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/12153

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BLANCO et al. Transcriptional factor TFIIB and the vitamin D receptor cooperatively activate ligand-dependent transcription. Proc. Natl. Acad. Sci. USA. February 1995, Vol. 92, pages 1535-1539, see entire document.	1-6
Y	METZ et al. C-fos-induced activation of a tata-box-containing promoter involves direct contact with TATA-box-binding protein. Molec. Cellul. Biol. September 1994, Vol. 14, No. 9, pages 6021-6029, see entire document.	1-6

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/12153

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, HCAPLUS, MEDLINE

search terms: retinoid (3a) receptor?, gal4 (2a) activation domain?, tbp, tata, taf110.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-6 and 11, drawn to a method to identify compounds and fusion protein.

Group II, claim(s) 7-8, drawn to an RXR mutant.

Group III, claim(s) 9-10, drawn to a method to identify agonists.

Group IV, claim(s) 12-17, drawn to a method to detect ligand dependent interactions.

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I is directed to a method to identify compounds and fusion protein. The special technical feature of Group I is a method to identify compounds. Group II is drawn to an RXR mutant which does not share the special technical feature of other groups. Group III and IV are additional methods which do not share the same or corresponding special technical feature with each other or other groups. Note that PCT Rule 13 does not provide for multiple products or methods within a single application. Since the special technical feature of each group invention is not present in any other group invention, unity of invention is lacking.

THIS PAGE BLANK (USPTO)